We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Kerry
Horne
kerry.horne@nottingham.ac.uk
Dr
Nicholas
Selby
nicholas.selby@nottingham.ac.uk
Kerry
Horne
kerry.horne@nottingham.ac.uk
Renal failure
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Renal perfusion, the delivery of oxygenated blood to kidney tissues, is important for both acute and chronic kidney diseases. Despite this, we do not have a way to measure renal perfusion in clinical practice. This is a major barrier to investigation and management of acute kidney injury (AKI) and chronic kidney disease (CKD). As these are conditions where cause and outcome vary significantly between individuals, measurement of kidney perfusion could improve assessment and allow treatment to be individualised.
The current non-invasive gold standard technique for renal perfusion measurement is arterial-spin labelling magnetic resonance imaging (ASL-MRI). However, MRI has limitations, including high cost and logistical barriers. Contrast Enhanced Ultrasound (CEUS) is a relatively inexpensive technique which can measure renal perfusion at the bedside. It uses a microbubble contrast agent, which allows continuous imaging of the vasculature and blood flow and is not damaging to the kidney. CEUS has been used to differentiate benign and malignant kidney masses, but its use in other forms of kidney disease is underdeveloped.
This proposal aims to compare MRI with CEUS measurement of renal perfusion in patients with chronic kidney disease (CKD). 10 people with CKD stages 3b and 4 (eGFR between 15-45ml/min/1.73m2) will be recruited. Participants will undergo two study sessions, consisting of one MRI scan and one renal CEUS scan. The ASL-MRI at the Sir Peter Mansfield Imaging Centre (SPMIC) will provide a quantitative measure of renal perfusion, and CEUS performed at the Renal Unit at the Royal Derby Hospital will provide the comparison. Our group is already working on a study using this protocol in younger and older healthy volunteers. This proposal would use the same protocol for patients with CKD, to determine the range of renal perfusion values seen in CKD.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Validation of investigation /therapeutic procedures;
You can take part if:
You may not be able to take part if:
Autosomal dominant polycystic kidney disease Solid organ transplant Pregnancy and breastfeeding contraindications to Sonovue ie. Known allergy to Sonovue, Recent acute myocardial infarction, class iii/iv heart failure, right to left cardiac shunts and severe pulmonary hypertension Contraindications to MRI
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Nicholas
Selby
nicholas.selby@nottingham.ac.uk
Kerry
Horne
kerry.horne@nottingham.ac.uk
Kerry
Horne
kerry.horne@nottingham.ac.uk
The study is sponsored by University of Nottingham and funded by KIDNEY RESEARCH UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 59992
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
